Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SPENDA LIMITED Board/Management Information 2005

Oct 19, 2005

65849_rns_2005-10-19_d961ae21-f303-4d57-ac57-2991829b4edb.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

COMPANY ANNOUNCEMENT

Appointment of new Director

19th October 2005: Premier Bionics is pleased to announce the appointment of Mr. Duncan Clegg as a Non-Executive Director. Based in London, Mr. Clegg has played an important role in the impending dual listing of the Company on AIM (as announced on $18th$ October 2005).

Mr. Clegg, aged 62, has had a long and distinguished career spanning the corporate finance, investment banking and industrial sectors. He is Chairman of Low & Bonar PLC, a specialist materials manufacturer, listed on the London Stock Exchange. He was previously an executive director of Lazard Brothers & Co., Limited (a leading international merchant banking group) where he acquired broad experience covering all facets of corporate finance. He was elected as Vice Chairman to the Port of London Authority on 1 September 2003 and is also a member of the Cook Society, which encourages business connections between Australia and the U.K..

Premier Bionics welcomes Mr. Clegg to the Board and looks forward to a valuable contribution from him as the Company rolls out its corporate strategy for the Northern Hemisphere.

For further information contact:

Executive Chairman: 03 9824 8166 Peter Marks.

Background on Premier Bionics

Premier Bionics was formed in December 2001 to invest in advanced, Australian-based research in medical devices and diagnostics. The company listed on the Australian Stock Exchange (ASX: PBI) in May 2002.

Premier Bionics' first investment was PulmoSonix Pty Ltd, a company formed to develop technology developed at Monash University's Ritchie Centre for Baby Health Research. Premier Bionics was also granted a 7-year exclusive right of first review, evaluation and commercialisation of technology produced by researchers at the Ritchie Centre in the field of respiratory disorders, sleep apnea and other sleep disorders, and chronic lung disease. Premier Bionics' second investment was made in April 2005 with the acquisition of Medic Vision Limited.

See www.premierbionics.com.au for more details.